儿童和青少年成熟B细胞非霍奇金淋巴瘤临床诊治探讨

临床儿科杂志 ›› 2014, Vol. 32 ›› Issue (5): 401-404.

• 专家笔谈 • 下一篇

儿童和青少年成熟B细胞非霍奇金淋巴瘤临床诊治探讨

高怡瑾

上海交通大学医学院附属上海儿童医学中心血液/肿瘤科(上海 200127）

收稿日期:2014-04-01 出版日期:2014-05-15 发布日期:2014-05-15

Treatment of childhood and adolescent mature B-cell lymphoma

GAO Yijin

(Shanghai Children’s Medical Center, Shanghai Jiaotong University, School of Medicine, Shanghai 200127, China)

Received:2014-04-01 Online:2014-05-15 Published:2014-05-15

摘要/Abstract

摘要：

　成熟B细胞非霍奇金淋巴瘤（B-NHL）占儿童和青少年非霍奇金淋巴瘤的55%~60%。以伯基特淋巴瘤和弥漫大B细胞淋巴瘤最为常见。短疗程的多药联合强化疗可使儿童和青少年B-NHL的总体生存率达80%以上。影响B-NHL预后的相关因素包括，骨髓或中枢神经系统受累与否、血清乳酸脱氢酶水平以及化疗后患儿的动态反应。在分子生物学水平上寻找新的危险因子，寻找新的治疗方法以减少治疗相关不良反应是未来临床研究的重点。文章就目前儿童和青少年B-NHL临床诊治要点进行回顾分析。

Abstract: Mature B-cell non-Hodgkin lymphoma (B-NHL) represents about 55%-60% of all NHL cases in children and adolescents. Burkitt lymphoma and diffuse large B-cell lymphoma are the most common subtypes. Current combination chemotherapy regimen succeeds in overall survival rates of more than 80%. Risk factors for the prognosis of childhood and adolescent B-NHL include, bone marrow and central nervous system involvement, serum lactate dehydrogenase level and kinetics of response to therapy. Future strategies should include further understanding of the genetic alternation of B-NHL and utilization of novel target therapies to decrease treatment-related toxicity. We performed a retrospective analysis on the treatment of child and adolescent mature B-cell lymphoma.

高怡瑾. 儿童和青少年成熟B细胞非霍奇金淋巴瘤临床诊治探讨[J]. 临床儿科杂志, 2014, 32(5): 401-404.

GAO Yijin. Treatment of childhood and adolescent mature B-cell lymphoma [J]. , 2014, 32(5): 401-404.

参考文献

[1] Hochberg J，Waxman IM，Kelly KM，et al. Adolescent non-hodgkin lymphoma and Hodgkin lymphoma：state of the science[J]. Br J Haematol，2009，144(1)：24-40.
[2] Bollard CM，Lim MS，Gross TG，et al. Children’s Oncology Group’s 2013 blueprint for research：non-Hodgkin lymphoma[J]. Pediatr Blood Cancer，2013，60(6)：979-984.
[3] Abla O，Weitzman S，Blay JY，et al. Primary CNS lymphoma in children and adolescents：a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)[J]. Clin Cancer Res，2011，17(2)：346-352.
[4] Patte C，Auperin A，Michon J，et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol：highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. [J] Blood，2001，97(11)：3370-3379.
[5] Patte C，Auperin A，Gerrard M，et al. Results of the randomized international FAB/LM96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents：it is possible to reduce treatment for the early responding patients[J]. Blood，2007，109(7)：2773-2780.
[6] Pillon M，Di Tullio MT，Garaventa A，et al. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92)[J].Cancer，2004，101(2)：385-394.
[7] Gerrard M，Cairo MS，Weston C，et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma：results of the FAB/LMB96 international study[J]. Br J Haematol，2008，141(6)：840-847.
[8] Woessmann W，Seidemann K，Mann G，et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms：a report of the BFM Group Study NHL-BFM95 [J]. Blood，2005，105(3)：948-968.
[9] Fujita N，Kobayashi R，Takimoto T，et al. Results of the Japan Association of Childhood leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hogkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood [J]. Leuk Lymphoma，2011，52(2)：223-229.
[10] Reiter A. Non-Hodgkin lymphoma in children and adolescents[J]. Klin Padiatr，2013，225 Supp1：S87-S93.
[11] Cairo MS，Gerrard M，Sposto R，et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents [J]. Blood，2007，109(7)：2736-2743.
[12] Reiter A. Diagnosis and treatment of childhood non-hodgkin lymphoma [J]. Hematology Am Soc Hematol Educ Program，2007：285-296.
[13] Miles RR，Arnold S，Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia [J]. Br J Haematol，2012，156(6)：730-743.
[14] Worch J，Rohde M，Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives [J]. Pediatr Hematol Oncol，2013，30(6)：465-483.
[15] Poirel HA，Cairo MS，Heerema NA，et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma：results of the FAB/LMB96 international study [J].Leukemia，2009，23(2)：323-331.
[16] Nelson M，Perkins SL，Dave BJ，et al. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact in survival in children and adolescents with Burkitt lymphoma：results from the Children’s Oncology Group study CCG-5961 [J]. Br J Haematol，2010，148(4)：600-610.
[17] Shiramizu B，Goldman S，Kusao I，et al. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (stage III/IV) B-cell non-Hodgkin lymphoma：a children’s oncology group report [J]. Br J Haematol，2011，153(6)：758-763.
[18] Reiter A，Schrappe M，Tiemann M，et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy：a report of the Berlin-Frankfurt-Müster Group Trial NHL-BFM 90 [J]. Blood.1999;49(10)：3294-3306.

儿童和青少年成熟B细胞非霍奇金淋巴瘤临床诊治探讨

Treatment of childhood and adolescent mature B-cell lymphoma

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

Metrics

本文评价

推荐阅读 0